Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19.

Libo Zhang,Yishan Zheng,Sheng Ye,Jingjing Bao,Zhiliang Hu,Xiang Xue,Yudong Dai,Rongrong Pang,Qiang Fu,Yongxiang Yi

doi:10.18632/aging.103102

Abstract

Background: Anti-SARS-CoV-2 virus antibody levels in convalescent plasma (CP), which may be useful in severe Anti-SARS-CoV-2 virus infections, have been rarely reported.Results: A total of eight donors were considered for enrollment; two of them were excluded because of ineligible routine check. Of the six remaining participants, five samples were tested weakly positive by the IgM ELISA. Meanwhile, high titers of IgG were observed in five samples. The patient treated with CP did not require mechanical ventilation 11 days after plasma transfusion, and was then transferred to a general ward.Conclusions: Our serological findings in convalescent plasma from recovered patients may help facilitate understanding of the SARS-CoV-2 infection and establish CP donor screening protocol in COVID-19 outbreak.Methods: Anti-SARS-CoV-2 antibodies including IgM and IgG were measured by two enzyme-linked immunosorbent assays (ELISA) in convalescent plasma from six donors who have recovered from coronavirus disease 2019 (COVID-19) in Nanjing, China. CP was also utilized for the treatment of one severe COVID-19 patient.

Highlights

By late 2019 the outbreak of coronavirus disease 2019 (COVID-19) was unchecked in China [1, 2]
We present our preliminary findings of anti-SARS-CoV-2 antibody levels in convalescent plasma obtained from six donors and clinical effects of one case treated with CP in Nanjing, China
We reported the serological findings of SARS-CoV-2 infection in a CP donor population

Summary

Introduction

By late 2019 the outbreak of coronavirus disease 2019 (COVID-19) was unchecked in China [1, 2]. In accordance with CP infusion therapeutics guidelines approved by the National Health Commission of People's Republic of China, we used ELISA to screen for anti-SARS-CoV-2 IgM and IgG. We present our preliminary findings of anti-SARS-CoV-2 antibody levels in convalescent plasma obtained from six donors and clinical effects of one case treated with CP in Nanjing, China. Anti-SARS-CoV-2 virus antibody levels in convalescent plasma (CP), which may be useful in severe Anti-SARS-CoV-2 virus infections, have been rarely reported. Conclusions: Our serological findings in convalescent plasma from recovered patients may help facilitate understanding of the SARS-CoV-2 infection and establish CP donor screening protocol in COVID-19 outbreak. Methods: Anti-SARS-CoV-2 antibodies including IgM and IgG were measured by two enzyme-linked immunosorbent assays (ELISA) in convalescent plasma from six donors who have recovered from coronavirus disease 2019 (COVID-19) in Nanjing, China. CP was utilized for the treatment of one severe COVID-19 patient

Methods

Results

Conclusion